| Literature DB >> 33806879 |
Nirmita Dutta1, Peter B Lillehoj2, Pedro Estrela3, Gorachand Dutta1.
Abstract
Cytokines are soluble proteins secreted by immune cells that act as molecular messengers relaying instructions and mediating various functions performed by the cellular counterparts of the immune system, by means of a synchronized cascade of signaling pathways. Aberrant expression of cytokines can be indicative of anomalous behavior of the immunoregulatory system, as seen in various illnesses and conditions, such as cancer, autoimmunity, neurodegeneration and other physiological disorders. Cancer and autoimmune diseases are particularly adept at developing mechanisms to escape and modulate the immune system checkpoints, reflected by an altered cytokine profile. Cytokine profiling can provide valuable information for diagnosing such diseases and monitoring their progression, as well as assessing the efficacy of immunotherapeutic regiments. Toward this goal, there has been immense interest in the development of ultrasensitive quantitative detection techniques for cytokines, which involves technologies from various scientific disciplines, such as immunology, electrochemistry, photometry, nanotechnology and electronics. This review focusses on one aspect of this collective effort: electrochemical biosensors. Among the various types of biosensors available, electrochemical biosensors are one of the most reliable, user-friendly, easy to manufacture, cost-effective and versatile technologies that can yield results within a short period of time, making it extremely promising for routine clinical testing.Entities:
Keywords: autoimmunity; biosensor; cancer; cytokine; electrochemical; neurodegeneration
Mesh:
Substances:
Year: 2021 PMID: 33806879 PMCID: PMC8004910 DOI: 10.3390/bios11030094
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Metabolic pathways of cytokines in humans. Reprinted from [4] with permission from PubMed Central.
Figure 2Schematic illustrations of (A) electrochemical immunosensor and (B) electrochemical aptasensor. (Agn = Antigen, Ab1 = Primary antibody, Ab2 = Secondary antibody, Apt = Aptamer, R = Reduced species, O = Oxidized species, V = Applied voltage, I = Current signal).
Aptasensors: Design and sensor preparation.
| Sl. No. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | SPGE/PPyNPs/AuNPs/Apt | [Fe(CN)6]4−/3− | Anti-IL-6 Apt | 6-mercaptohexanol | SPGE+ Py+ LiClO4 → polymerization: multipulse amperometry |
| 2. | Apt/AuNP/Au electrode | [Fe(CN)6]4−/3− | Anti-IL-6 Apt | HS-(CH2)11(OCH2CH2)3OH | Au electrode/AuNP+ Aptamer(thiolated): Au-S chemistry |
| 3. | Au/Apt-MB | MB (ox/red) | Anti-TNFα Apt | 6-mercapto-1-hexanol | 28-mer RNA Apt nucleotides are phosphorothiolated to protect from RNase |
| 4. | Au/Apt-MB | MB (ox/red) | Anti-IFNγ Apt | 6-mercapto-1-hexanol | 3’ NH2-(CH2)6-Apt+ MB-NHS → 3’ MB-NH-(CH2)6-Apt or MB-Apt |
| 5. | Au/capture probe | 1-naphthol (red → ox) | Anti-IFNγ Apt | 6-mercapto-1-hexanol | Au+ 5’ SH-capture probe: immobilization with Au-S chemistry |
| 6. | Au/Apt | [Fe(CN)6]4−/3− | Anti-IFNγ Apt | β-mercaptoethanol | Deactivation of RNase in solutions with diethyl pyrocarbonate (DEPC) |
| 7. | Au/Apt-MB | MB(ox/red) | Anti-TGF-β1 Apt | 6-mercapto-1-hexanol | MB-NHS+ 5’ NH2-Apt: covalent linkage; MB-Apt formation |
Common abbreviations: SPGE = Screen printed graphite electrode, PPyNP = Poly pyrrole nanoparticles, AuNP = Gold nanoparticles, H1, H2 = DNA hairpins, Bt= Biotin, SAv = Streptavidin, ALP = Alkaline Phosphatase, MB = methylene blue; Apt = Aptamer; MB-NHS = methylene blue, carboxylic acid, succinimidylester, EG3 = HS-(CH2)11(OCH2CH2)3OH, an oligo(ethylene oxide), TCEP = tris-(2-carboxyethyl)phosphine hydrochloride.
Aptasensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | EIS | 0.33 pg/mL | 1 pg/mL–15 μg/mL | BSA, CEA, MUC1, MUC4, MUC16 | +IL-6/30 min | IL-6 in PBS | (6 assays) | - | - |
| 2. | EIS | 0.02 pg/mL | 0.02–20 pg/mL | BSA | - | IL-6 in buffer | (5 assays, at [IL-6] = 0.02 pg/mL) RSD = 14.1% | After 2 weeks- 90% of initial signal retained for [IL-6] = 0.2 pg/mL | 90% of initial signal retained for [IL-6] = 0.02 pg/mL |
| 3. | SWV | 58 pM | 58 pM–6 nM | - | Sensor equilibration/30 min | rTNFα in spiked whole blood | - | Stable over 10 h | After 6 cycles & regeneration/urea, 90% of original signal retained |
| 4. | SWV | 0.06 nM | 0.06–10 nM | IgG, anti-IgG, BSA | +IFNγ/15 min | rIFNγ in HEPES buffer | - | - | Regeneration/urea/1min + rinsing/diH2O; sensor can be reused more than 10 or more times |
| 5. | DPV | 0.3 nM | 0.5–300 nM | PDGF-BB, BSA, IgG, CEA, IL-6 | IFNγ+ recognition probe/2 h | IFNγ in HEPES buffer | - | After 2 weeks, no significant change in current response | Regeneration/NaOH/20 min + washing/diH2O/10 min; sensor can be reused more than 3 times |
| 6. | EIS | 500 fM (RNA Apt) | - | BSA, FBS | +IFNγ/30 min | IFNγ in PBS | - | - | - |
| 7. | SWV | 1 ng/mL | 1–200 ng/mL | IL-2, IFNγ, BSA, IgG, TGF-β2, TGF-β3 | (real-time detection at constant flow) | rTGF-β1 in cell culture media DMEM | - | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, CEA = Carcinoembryonic antigen, MUC = Mucin protein, Ig = Immunoglobulin protein, PDGF = Platelet-derived growth factor, FBS = Fetal bovine serum, HEPES = (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), DMEM = Dulbecco’s Modified Eagle Medium.
Enzyme-labeled immunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | ITO/PDOP-AuNP/Ab1 | 1,2-phenylenediamine/2,2’-diaminoazobenzene | Anti-IL-6 Ab1, Ab2 | BSA | ITO + Dopamine + AuNP: polymerization of dopamine, AuNP absorption |
| 2. | PG/PDDA/GSH-AuNP/Ab1/BSA | Hydroquinone/benzoquinone | Anti-IL-6 Ab1, Ab2 | GSH + AuNP: Au-S chemistry | |
| 3. | ITO/PDDA/AuNP/Ab1 | Hydroquinone/benzoquinone | Anti-IFNγ Ab1, Ab2 | BSA | ITO electrode + PDDA: drop-casting |
| 4. | SPCE-Phen-Ab1 | Hydroquinone/benzoquinone | Anti-IFNγ Ab1, Ab2 | BSA | p-aminobenzoic acid (p-ABA) + NaNO2/HCl → p-ABA diazonium salt |
| 5. | Mb-Ab1 | Hydroquinone/benzoquinone | Anti-TGF-β1 Ab1, Ab2 | Ethanolamine | MB-COOH+ Mix&Go polymer + Ab1: covalent immobilization |
| 6. | SPCE/SAv-Bt-Ab2 | (C5H4N(CH2)2NH2)1+/2+ or V1+/2+ | Anti-TGF-β1 Ab1, Ab2 | Biotin | SWCNT + p-aminobenzoic acid (p-ABA) + isoamylnitrile/NMP → SWCNT-Phe-COOH; grafting |
| 7. | SPCE/MWCNT-alkyne-azide-IgG | Hydroquinone/benzoquinone | Anti-TGF-β1 Ab1, Ab2 | Casein | MWCNT(-COOH gr.) + 11-azide-3,6,9-trixaundecan-1-amine: amide bond formation with EDC/NHS catalyst |
| 8. | PMMA/PCB/Au/Fab1-cys | 3,3’,5,5’-tetramethylbenzidine (TMBox/TMBred) | Anti-IFNγ Fab1, Ab2 | BSA | PMMA/PCB containing Au plated microchannels+ Fab-cys: Au-S chemistry |
| 9. | GCE/PANA/Ab1 | α-naphthol (1-NP) (red→ox) | Anti-TNFα Ab1, Ab2 | BSA | Styrene + acrylic acid + K2S2O8: polymerization into PSA spheres |
| 10. | Si/SiO2/Au/PMMA/FNAB/Ab1 | 4-aminophenol (4AP)/quinoneimine(QI) | Anti-TNFα Ab1, Ab2 | StartingBlock T20 (PBS) blocking buffer | PMMA sheet: laser-engraved, with fluidic channels punched |
| 11. | SPCE/MWCNT-IgG | 1-naphthol (red→ox) | Anti-IL-1β Ab1, Ab2 | Caesin | CuSO4: Cu(II)→Cu(I); electrochemical reduction |
| 12. | GCE/Fc-PNW/PDDA/AuNP/Ab1 | Fe2+/3+ of Ferrocene | Anti-TNFα Ab1, Ab2 | BSA | Boc-Phe-Phe-OH + H-Phe-OMe + HBTU/HOBT/CH2Cl2, Et3N → Boc-Phe-Phe-OMe; separated by column chromatography |
Common abbreviations: PDOP = polydopamine, PG = Pyrolytic graphite, GSH = Glutathione, PDDA = poly(diallyldimethylammonium chloride), Phen = Phenyl gr., Mb = Magnetic bead, V = Viologen (C5H4NR)22+ where R = modified alkyl group, CNT = Carbon nanotube, SWCNT = Single-walled CNT, MWCNT = Multi-wall CNT, PMMA = Polymethyl methacrylate, PCB = Printed circuit board, Fab1 = antigen binding fragment, cysteine terminated, PANA = polyaniline doped with poly(acrylic acid), PSA = poly(styrene-acrylic acid), PAH = polyallylamine hydrochloride, PMMA = Polymethyl methacrylate, FNAB = 4-fluoro-3-nitroazidobenzene, Fc = ferrocene, PNW = peptide nanowires/diphenylalanine, GNR = gold nanorods, AuNP = Gold nanoparticles, ITO = Indium tin oxide, GCE = Glassy carbon electrode, SPCE = Screen printed carbon electrode, ALP = alkaline phosphatase, HRP = horseradish peroxidase, GOx = Glucose oxidase, Bt = Biotin, Av = Avidin, SAv = Streptavidin; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, DCC = N,N’-dicyclohexylcarbodiimide, NHS = N-hydroxysuccinimide, NHSS = N-hydroxysulfo-succinimide, HOBt = Hydroxybenzotriazole, PAA = poly(acylic acid), Boc = Butoxycarbonyl gr., Phe = Phenylalanine, Me = Methyl gr., HBTU = Hydroxybenzotriazole, HOBT = 2-(1H-bemzotriazole-1yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, Et3N = Trimethylamine, CTAB = Cetyltriethylammonium bromide.
Enzyme-labeled immunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CA | 1.0 pg/mL | 4–800 pg/mL | AFP, CEA, hIgG, L-cys, L-lys, Glucose | +IL-6/1h | IL-6 in buffer | Intra-assay precision (5 readings per run, at [IL-6] = 40 pg/mL) SD = 5.5% | After 30 days- 85.5% of initial signal retained | - |
| 2. | Rotating disc amperometry | 10 pg/mL | 10–4000 pg/mL | - | +IL-6/1 h | Recombinant human IL-6 (rhIL-6) in calf serum | Sensitivity: 1.6 nA/cm2 (pg/mL IL-6) | ||
| 3. | DPV | 0.048 pg/mL | 0.1–10,000 pg/mL | BSA, AA, glucose, UA, IL-22 | +IFNγ/2 h | IFNγ in PBS | (5 assays, at [IFNγ] = 0.1 ng/mL) RSD = 2.7% | After 2 weeks, 92% of initial signal retained | (disposable) |
| 4. | CA | 1.6 pg/mL | 2.5–2000 pg/mL | AA, BSA, Glucose, Hb, hIgG, IL-1β, IL-6, IL-8, RANKL, TGF-β1, TNFα, UA | +IFNγ/60 min | IFNγ in PBS | (5 assays, same day, at [IFNγ] = 1 ng/mL) RSD = 1.8% | Within 40 days, retained signal acceptable | - |
| 5. | CA | 10 pg/mL | 15–3000 pg/mL | AA’, UA, Creatinine, APN, IL-6, IL-8, TNFα | +TGF-β1/60 min | TGF-β1 in ELISA standard solution | (5 assays, same day, at [TGF-β1] = 250 pg/mL) RSD = 3.9% | Signal within control limits within 30 days | - |
| 6. | CA | 0.95 pg/mL | 2.5–1000 pg/mL | AA’, APN, BSA, Cortisol, IgG, IL-1β, IL-6, IL-8, TNFα, UA | +TGF-β1/60 min | TGF-β1 in ELISA standard solution | (5 assays, same day, at [TGF-β1] = 125 pg/mL) RSD = 3.1% | Signal within control limits for: (i) SPCE/SAv-Bt-Ab2, within 30 days; (ii) V-Phe-SWCNT(-HRP)-Ab1, within 14 days | - |
| 7. | CA | 1.3 pg/mL | 5–200 pg/mL | APN, BSA, BR, CP, TNFα, GHRL, Hb, IL-6, IL-8, CRP, Chl, TGF-β2, TGF-β3, TGF-β5 | +TGF-β1, Bt-Ab2/60 min | TGF-β1 in ELISA standard solution | (5 assays, same day, at [TGF-β1] = 125 pg/mL) RSD = 2.7% | Signal within control limits within 40 days | - |
| 8. | CA | 126.75 pg/mL | 15–1000 pg/mL | TREM-1 | +Fab1-cys/60 min | IFNγ in ELISA standard solution | - | - | - |
| 9. | DPV | 0.01 ng/mL | 0.02–200 ng/mL | CEA, BSA, hIgG | +TNFα/1 h | TNFα in buffer | Intra-assay precision (7 runs, at [TNFα] = 5 ng/mL) RSD=5.7% | After 1 month, 95% of initial response retained | - |
| 10. | DPV | 66.8 pg/mL | 0.1–100 ng/mL | IL-2, IFNγ | +TNFα/20 min | TNFα in spiked undiluted serum | - | Until 6 weeks, 96% of initial signal was retained, after which it dropped to 90% by 9th week | - |
| 11. | DPV | 5.2 pg/mL | 1st slope: 10–200 pg/mL; | BR, TGF-β1, LEP, IL-8, IL-6, Hb, Chl, BSA, GHRL, TNFα | +IL-1β/1 h | IL-1β standard solution | (10 assays, same day, at [IL-1β] = 1 ng/mL) RSD = 5.2% | Signal within control limits within 10 days | (disposable) |
| 12. | SWV | 2 pg/mL | 0.005–10 ng/mL | - | +TNFα/1 h | TNFα in buffer | (6 assays, at [TNFα] = 0.1 ng/mL) RSD = 5.4% | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, CEA = Carcinoembryonic antigen, hIg = Human immunoglobulin protein, AFP = α-1-fetoprotein, CRP = C-reactive protein, L-cys = L-cysteine, L-lys = L-lysine, AA = Abscisic acid, UA = Uric acid, RANKL = Receptor activator of nuclear factor kappa-B ligand, AA’ = Ascorbic acid, APN = Adiponectin, BR = Bilirubin, CP = Cerculoplasmia, GHRL = Ghrelin, Hb = Hemoglobin, Chl = Cholesterol, LEP = Leptin, TREM1 = Triggering receptor expressed on myeloid cells 1.
SAM-enabled impedimetric immunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | Si/SiO2/SWCNT/AuNP/Ab | [Fe(CN)6]4−/3− | Anti-IL-6 Ab | BSA | Si/SiO2/SWCNT: prepared by ethanol chemical vapor condensation on Si/SiO2 wafer substrate |
| 2. | Au/CMA/Ab | [Fe(CN)6]4−/3− | Anti-TNFα Ab | Ethanolamine | Au microelectrodes+ CMA: Diazotization of CMA in presence of NaNO3, HCl; electrodeposition on Au by CV |
| 3. | ITO/P3/Ab | [Fe(CN)6]4−/3− | Anti-TNFα Ab | BSA | ITO(-OH gr.) + P3(-COOH gr.): ester bond formation: SAM formation |
| 4. | Au/NAC/Ab | - | Anti-IFNγ Ab | Ethanolamine | Au electrode+ acetylcysteine: SAM formation by Au-S chemistry |
| 5. | Au/PEG/anti-TGF-β1 Ab, anti-HA Ab | [Fe(CN)6]4−/3− | Anti-TGF-β1 Ab | - | Cr-Au layered interdigited electrodes prepared with lithography + etching |
| 6. | PI/Au-Ab | [Fe(CN)6]4−/3− | Anti-IL-10 Ab | - | Au layered on PI by soft lithography + etching |
| 7. | Si/HfO2/TESUD/Ab | - | Anti-IL-10 Ab | MeO-PEG-NH2 in triethylamine | HfO2 grown on Si substrate by atomic layer deposition |
| 8. | Si/Au/DSP/Ab/EA | [Fe(CN)6]4−/3− | Anti-TNFα Ab | Ethanolamine | Si/Ti/Au microelectrode arrays preparation: photolithography, etching |
| 9. | Si/SiO2/Ti-Au/mcp | - | Anti-IL-8 mcp | Ethanolamine | Phage display selection of IL-8 binding Ab-mimetic capture protein |
| 10. [ | Si/SiO2/Ti:Au disc/Ab needle-shaped microelectrode | [Fe(CN)6]4−/3− | Anti-IL-6 Ab | 6-mercapto-1-hexanol | Si/SiO2/Ti:Au disc: lift-off lithography; reactive ion etching |
| 11. | AuNP-Ab2 | [Fe(CN)6]4−/3− | Anti-IL-6 Ab1, Ab2 | BSA | AuNP: citrate reduction of HAuCl4 |
Common abbreviations: CMA = 4-carboxymethylaniline, AuNP = Gold nanoparticles, CNT = Carbon nanotube, SWCNT = single-walled CNT, ITO = Indium tin oxide, P3 = poly(3-thiophene acetic acid), NAC = N-acetylcysteine, Me = methyl group, PEG = polyethylene glycol, HA = Hyaluronic acid, PI = Polyimide, TESUD = (11-triethoxysilyl)undecanal, DSP = Dithiobis-succinimidyl propionate, EA = ethanolamine, mcp = recombinant Ab-mimetic capture protein, MUA = 11-mercaptoundecanoic acid, CTAB = cetyltrimethylammonium bromide; Ab1 = capture antibody, Ab2 = signal antibody; PDMS = polydimethylsiloxane, EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide, Sulfo-LC-SPDP = Sulfosuccinimidyl 6-[3’-(2-pyridyl dithio) propionamido] hexanoate, DTT = Dithiothreitol, TCEP = tris(2-carboxyethyl) phosphine hydrochloride.
SAM-enabled impedimetric immunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | EIS | 0.01 fg/mL | 0.01–100 fg/mL | Serum, glucose, cysteine, Epinephrine | - | IL-6 in buffer | - | After 1 month- initial Rct retained | - |
| 2. | EIS | - | 1–15 pg/mL | rhIL-8 | +TNFα/30 min | rTNFα in PBS | - | - | No significant change in signal after 3 subsequent detections |
| 3. | EIS | 3.7 fg/mL | 0.01–2 pg/mL | Drugs- ampicillin, amoxicillin, erythromycin, clarithromycin, acetylsalicylic acid; Proteins- biotin, albumin; Biomarkers- SOX2, MAGE1, RACK1, HER2, VEGFR | 45 min | TNFα in PBS | 80 electrodes used to draw 10 calibration plots; RSD of slopes = 2.5% | After 8 weeks, impedance decreased to 50% of initial value | Good response for 6 cycles |
| 4. | EIS | 0.02 fg/mL | 0–12 pg/mL | IL-2 | - | rIFNγ in PBS | - | - | Removal of non-specifically adsorbed proteins/KCl solution, regeneration with: SAM wipeout/thioctic acid/potential pulses+ SAM reassembly; 10% repeatability |
| 5. | EIS | 0.57 ng/mL | 1–1000 ng/mL | BSA | +TGF-β1, HA/30 min | TGF-β1 in PBS | - | - | - |
| 6. | EIS | - | 1–15 pg/mL | - | - | IL-10 in buffer | - | - | - |
| 7. | EIS | 0.1 pg/mL | 0.1–20 pg/mL | TNFα, IL-1β | +IL-10/1 h | rh1L-10 in PBS | - | - | - |
| 8. | EIS | ~57 fM | 1–100 pg/mL | IFNγ | +TNFα/15 min | TNFα in culture media | - | - | - |
| 9. | EIS | 90 fg/mL | 0.0009–900 ng/mL | BSA | +IL-8/15 min | IL-8 in spiked horse serum | - | - | - |
| 10. | DPV | - | - | BSA, Enterotoxin A | +IL-6/2.5 min (real-time detection) | IL-6 in PBS | - | - | - |
| 11. | SWV | 2 pg/mL | 0.005–50 ng/mL | hIgG, lysozyme, BSA, AFP | +IL-6/1 h | IL-6 in PBS | (6 assays, at [IL-6] = 10 ng/mL) RSD = 7.9% | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, rhIL = Recombinant human interleukin, BSA = Bovine Serum Albumin, hIg = Human immunoglobulin protein, SOX2 = Sex determining region Y-box 2, MAGE1 = Melanoma associated antigen 1, RACK1 = Receptor for activated C kinase 1, HER2 = Human epidermal growth factor receptor, VEGFR = vascular endothelial growth factor receptor, AFP = α-1-fetoprotein.
Heavy metal nanoparticle-labeled immunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | Ab2-AgNP-TiP | Ag0/1+ | Anti-IL-6 Ab1, Ab2 | BSA | AgNP + TiP: ion exchange |
| 2. | GCE/PDDA-RGO-AuNP-PDA/IL-6/BSA | Cd1+/2+ | Anti-IL-6 Ab | BSA | AuNP-PDA: by reduction of HAuCl4, oxidation and polymerization of dopamine (DA) |
| 3. | Ab2/PS@PDA/AgNP | Ag0/1+ | Anti-IL-6 Ab1, Ab2 | - | PS + DA (dopamine): Self polymerization of DA; adhesion of PDA to PS |
| 4. | SiNP/PGMA/CdTe QD/Ab2 | Cd1+/2+ | Anti-TNFα Ab1, Ab2 | BSA | SiO2 NP + APTES/toluene: SiO2-NH2 NP formation |
| 5. | MNP/PANI/Ab1 | Cd1+/2+ | Anti-IFNγ Ab1, Ab2 | Casein/tris buffer for AuNP | MNP + PANI: coating |
Common abbreviations: TiP = Titanium phosphate hollow spheres, PDDA = poly(diallyldimethylammonium chloride), RGO = graphene oxide, PDA = polydopamine, CdTe QDs = Cadmium telluride quantum dots, HCPE = heated carbon paste electrode, PS = Polystyrene, GNR = Graphene nanoribbons, SiNP = silica nanoparticles, PGMA = poly(glycidyl methacrylate), PAB = poly(abscisic acid), MNP = magnetic nanoparticles, PANI = polyaniline, CNT = Carbon nanotube, GCE = Glassy carbon electrode, BFE = Bismuth film modified GCE, AuNP = Gold nanoparticles, AgNP = Silver nanoparticles, SPCE = Screen printed carbon electrode, HSPCE = Heated SPCE; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide.
Heavy metal nanoparticle-labeled immunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Electrodeposition followed by stripping with DPV | 0.1 pg/mL | 0.0005–10 ng/mL | TNF-α, | +IL-6/40 min | IL-6 in PBS | (2 assays) RSD = 8.0% | After 2 months- 94.2% of initial signal retained | - |
| 2. | ASV | 0.033 pg/mL for HCPE | 0.1–100 pg/mL for HCPE | CEA, CRP, TNF-α, BSA | +IL-6, +CNT@CdTe QDs-Ab/40 min | IL-6 in buffer | (5 assays, at [IL-6] = 10 pg/mL) RSD = 4.1% | After 1 week- >90% of initial signal retained | - |
| 3. | Stripping SWV | 0.1 pg/mL | 0.001–1000 ng/mL | BSA, CEA, CTnI, IgG | +IL-6/50 min | IL-6 in buffer | (5 assays) initial signal significantly retained at [IL-6] = 0.1 ng/mL | After 2 weeks- initial signal not significantly changed | - |
| 4. | SWV | 3.0 pg/mL | 0.01–100 ng/mL | - | AuNP-PAB-Ab1 + TNFα/45 min | TNFα in buffer | Intra-assay precision (4 runs) CV=5.1% | After 2 weeks, no apparent change in signal | After 6 cycles & regeneration/glycine-HCl, 95.7% of initial signal retained |
| 5. | SWASV | 0.4 pg/mL | 0.01–1 IU/mL | - | IFNγ + MNP/PANI/Ab1/20 min | IFNγ in PBS | - | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, CEA = Carcinoembryonic antigen, hIg = Human immunoglobulin protein, CRP = C-reactive protein, CTnI = Cardiac Troponin I.
Redox-labeled immunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | GCE/GO-Ab1 | Fe2+/3 + of Fc | Anti-IL-6 Ab1, Ab2 | BSA | CaCO3 + PDDA + PSS + Fc: Adsorption |
| 2. | CeO2/CS-PB-Ab2 | PB (Fe2+/2+/Fe2+/3+/Fe3+/3+) | Anti-TNFα Ab1, Ab2 | BSA | CeO2 NP/CS (+ve) + Fe(CN)63−: Adsorption |
| 3. | GCE/K-CS-GA/Ab | [Fe(CN)6]4−/3− | Anti-TNFα Ab | BSA | CS (-NH2 gr.) + GA (-CHO gr.) + K3[Fe(CN)6]: crosslinking with imine bond formation; doping with K3[Fe(CN)6] |
| 4. | GCE/ZnO NP/Ab | [Fe(CN)6]4−/3− | Anti-IFNγ Ab | BSA | Zn(NO3)2 + H2N2 → ZnO NP |
| 5. | SPCE/Av/Bt-Ab1 | Guanine (irreversible oxidation) | Anti-TNFα Ab1, Ab2 | BSA | SiNP(-NH2 gr.) + glutaric anhydride + dimethylformamide: SiNP(-COOH gr.) |
Common abbreviations: PPN = Porous polyelectrolyte nanoparticles composed of poly(diallyldimethylammonium chloride (PDDA) and Poly(styrene sulfonate) (PSS), Fc = Ferrocene, GO = Graphene oxide, PB = Prussian blue nanoparticles, K = K4[Fe(CN)6], CS = Chitosan, GA = Glutaraldehyde, N = Nafion, SiNP = silica nanoparticles, G = guanine nucleotide, Bt = Biotin, Av = Avidin, poly[G] = 5’ NH2-(CH2)12-(G)10/20 3’, SPCE = Screen printed carbon electrode, GCE = Glassy carbon electrode, CNT = Carbon nanotubes, AuNP = Gold nanoparticles; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide.
Redox-labeled immunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SWV | 1 pg/mL | 0.002–20 ng/mL | hIgG, Lysozyme, | +IL-6/1 h | IL-6 in PBS | (6 assays) RSD = 5.8% | After 30 days- 90% of initial signal retained | 92.3% of initial signal retained after 6 regeneration cycles |
| 2. | CA | 2 pg/mL | 0.005–5 ng/mL | PSA, AFP, CEA | +TNFα/1 h | TNFα in buffer | Intra-assay precision (5 runs, at [TNFα] = 1 ng/mL) RSD = 4.6% | After 2 weeks, negligible current variation | - |
| 3. | CV | 10 pg/mL | 0.02–34 ng/mL | CA-125, CA-153, CA 19–9, AFP | +TNFα/1 h | TNFα in PBS | (5 assays, at [TNFα] = 1 ng/mL) RSD = 3.2% | - | - |
| 4. | EIS | 0.12 pg/mL | 0.0001–0.1 ng/mL | - | +IFNγ/80 min | rIFNγ in PBS | Intra-assay precision (6 runs, at [IFNγ] = 0.01ng/mL) CV = 4.1% | After 60 days, no apparent change in Rct | - |
| 5. | SWV | 2 pM | - | - | +TNFα/45 min | TNFα in PBS | (6 runs, at [TNFα] = 1 ng/mL) RSD = 9.8% | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, CEA = Carcinoembryonic antigen, hIg = Human immunoglobulin protein, AFP = α-1-fetoprotein, PSA = Prostate specific antigen, CA-125 (or -153, 19–9) = Cancer antigen-125.
Magnetoimmunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | Mb/anti-albumin Ab | [Fe(CN)6]4−/3− | Anti-TNFα Ab | - | Mb(-COOH gr.) + anti-(albumin/IgG/TNFα) Ab: amide bond formation with EDC/NHS catalyst |
| 2. | Mb/Ab1 | Hydroquinone/Benzoquinone | Anti-TNFα Ab1, Ab2 | Ethanolamine | Mb(-COOH gr.) + Ab1, |
| 3. | SPGE (with magnetic bars) | 1-naphthol (1-NP) (red → ox) | Anti-TNFα Ab1, Ab2 | Rabbit IgG | Mb/Protein G + Ab1: affinity bonding |
Common abbreviations: CSGM = Comb structured Au microelectrode, SPCE = Screen printed carbon electrode, SPGE = Screen printed graphite electrode, Mb = magnetic bead, Bt = Biotin, SAv = Streptavidin, HRP = Horseradish peroxidase, ALP = Alkaline phosphatase; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide.
Magnetoimmunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | EIS | 1 pg/mL | 1–1000 pg/mL | IL-2 | +Mb/anti-(albumin & IgG) Ab/1 h | TNFα in PBS | - | - | - |
| 2. | CA | 2.0 pg/mL (standard solution) | - | hIgG, BSA | +TNFα/1 h | rTNFα in PBS-Tween20 | (5 assays, same day) RSD = 5.7% | After 2 weeks, no significant decrease in S/N (signal/noise) ratio | - |
| 3. | DPV | 0.044 ng/mL | - | - | Mb +TNFα +Bt-Ab2/2 h | TNFα in PBS-Tween20 | In array (8 assays) RSD = 4%; | - | (disposable) |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, hIg = Human immunoglobulin protein.
Flow-injection/microfluidic immunosensors: Design and sensor preparation.
| Sl. no. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | HRP-Ab-AuNP/BSA/SPGE | Thionine (TH/TH(H+)) | Anti-IL-6 Ab | BSA | HRP-Ab + AuNP + BSA: entrapment, covalent bonding with glutaraldehyde |
| 2. | Au/cysteamine/BDE/Ab | - | Anti-IL-6 Ab | 1-dodecanethiol | Au rods + cysteamine + BDE + Ab: Au-S bond formation; cross-linking of Ab and cysteamine with BDE |
| 3. | APCPG/Ab1 | p-aminophenol (pAP)/p-benzoquinoneimine (QI) | Anti-IL-6 Ab1, Ab2 | Skim milk | APCPG + glutaraldehyde + Ab1: imine bond formation |
| 4. | SPPE/PANI-G/Ab | [Fe(CN)6]4−/3− | Anti-IFNγ Ab | BSA | Paper (wax-printed) + aniline/H2SO4: Electropolymerization by CV |
Common abbreviations: SPGE = Screen printed graphite electrode, BDE = 1,4-butanediol diglycidyl ether, APCPG = 3-aminopropyl- modified controlled-pore glass, SPPE = Screen printed paper electrode, PANI = polyaniline, G = graphene; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide.
Flow-injection/microfluidic immunosensors: Specifications and performance characteristics.
| Sl. no. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DPV | 1.0 ng/L | 5–100 ng/L | - | +IL-6/45 min | IL-6 in acetate buffer | Intra-assay precision (5 runs, at [IL-6] = 50 ng/L) CV = 4.7% | After 10 days- 77.6% of initial signal retained | (one-time use, disposable biosensor) |
| 2. | Potentiostatic detection | - | 0.5 fM–0.5 pM | IL-2 | 10 min | rIL-6 in PBS/Tween20/NaN3 | 30–40% | - | (sensor cannot be regenerated) |
| 3. | CA | 0.41 pg/mL | - | - | 25 min = | IL-6 standard solution (ELISA kit) | Intra-assay precision (5 runs, at [IL-6] = 200 pg/mL) CV = 2.74% | - | sensor could be used for ≥ 100 determinations following regeneration with glycine-HCl desorption buffer+ PBS washing |
| 4. | EIS | 3.4 pg/mL | 5–1000 pg/mL | BSA | +IFNγ/30 min | rIFNγ in PBS | RSD < 5% (5 assays) | After 2 weeks, 94% of initial Rct retained | (disposable) |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin.
FET-based biosensors: Design and sensor preparation.
| Sl. No. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | SiO2/GO-Ethanol/Ab liquid-gate | - | Anti-IL-6 Ab | BSA | SiO2 + APTES + GO: Silanization, electrostatic attachment |
| 2. | Si/SiO2/SWCNT/PASE/Apt liquid gate | - | Anti-IL-6 RNA Apt | - | SWCNT + PASE: pyrene rings adsorption onto sidewalls of nanotube |
| 3. | PDMS/G/Apt gate | - | Anti-IFNγ Apt | - | Graphene grown with low pressure chemical vapor deposition |
Common abbreviations: GO = Graphene oxide flakes, SWCNT = Single-wall carbon nanotube, PASE = 1-pyrenebutanoic acid, succinimidyl ester, PDMS = polydimethylsiloxane, G = graphene monolayer; Ab = antibody, Apt = aptamer; APTES = (3-aminopropyl)triethoxysilane.
FET-based biosensors: Specifications and performance characteristics.
| Sl. No. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | FET based detection | 4.7 pg/mL | - | - | - | IL-6 in buffer | - | - | - |
| 2. | FET based detection | 1 pg/mL | 1–100 pg/mL | BSA, PBS | (real-time detection) | IL-6 in MgCl2/PBS | - | - | - |
| 3. | FET based detection | 83 pM | ~0 nM- ~10 µM | BSA, Papain | - | rIFNγ in PBS | - | - | - |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin.
Biosensors for multiplexed cytokine detection: Design and sensor preparation.
| Sl. No. | Transducer Components | Redox Species | Bio-Recognition Element | Blocking Agent | Preparation and Immobilization (Brief) |
|---|---|---|---|---|---|
| 1. | GCE/Graphene-Chitosan/AuNP/anti-IL-6 Ab1, anti-IL-17 Ab1 | Cd1+/2+ | Anti-IL-6 Ab1, Ab2 | BSA | PVP/C2H5OH + AIBN + St + Cd(NO3)2: synthesis of PS-Cd2+ |
| 2. | (1) SiNW/APTES-Glu-anti-IL-6 Ab gate | - | Anti-IL-6 Ab | Ethanolamine | SiNW fabricated with top-down method |
| 3. | (1) Si/SiO2/Ti-Ni-Au/CMA/anti-IL-10 Ab | [Fe(CN)6]4−/3− | Anti-IL-10 Ab | - | Ti, Ni, Au trilayer deposited on SiO2/Si by physical vapor deposition; microelectrode designed by photolithography + etching |
| 4. [ | SPdCE | Hydroquinone/benzoquinone | Ab, hcDNA | Ethanolamine | Mb-COOH + Ab1(-NH2 gr.): amide bond formation with EDC/NHS catalyst |
Common abbreviations: AuNP = Gold nanoparticles, GCE = Glassy carbon electrode, PS = Polystyrene, PDDA = Poly(diallyldimethylammonium chloride), Fc = Ferrocene, SiNW = Silicon nanowires, APTES = (3-aminopropyl)triethyoxy-silane, Glu = glutaraldehyde, CMA = 4-carboxymethyl aryl diazonium salt, SPdCE = Screen printed dual carbon electrode, Mb = magnetic bead, HRP = Horseradish peroxidase, Bt = Biotin, SAv = Streptavidin, hcDNA = hairpin, complementary DNA, tDNA = target, synthetic DNA; Ab1 = capture antibody, Ab2 = signal antibody; EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS = N-hydroxysuccinimide, PVP = Polyvinylpyrrolidone, AIBN = 2,2’-azobisisobutyronitrile, St = Styrene.
Biosensors for multiplexed cytokine detection: Specifications and performance characteristics.
| Sl. No. | Detection Technique | Limit of Detection | Range of Detection | Interfering Species Tested | Incubation Time | Sample Type | Reproducibility | Stability | Repeatability |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SWV | IL-6: 0.5 pg/mL | IL-6: 1–1000 pg/mL | PSA, hIgG, TNFα | +IL-6, IL-17/1 h | IL-6, IL-17 in buffer | (5 assays, at [IL-6] = 10 pg/mL, [IL-17] = 10 pg/mL) RSD ≤ 4.8% | - | - |
| 2. | FET based detection | IL-6: 100 fg/mL | - | Leptin, Resistin | (real-time) | TNFα, IL-6 in: | - | - | - |
| 3. | EIS | IL-10: 0.3 pg/mL | IL-10: 1–15 pg/mL | IL-6 | +IL-10 or IL-1β/30 min | IL-10 or IL-1β in buffer | - | - | - |
| 4. | CA | IL-8 mRNA: 0.21 nM | - | (1) IL-8 mRNA WE: Non-complementary DNA, single base-mismatched DNA | (1) Mb-SAv+ Bt-hcDNA/60 min | IL-8, Bt-tDNA in: | (5 assays, at [IL-8 mRNA] = 2.5 nM, [IL-8 protein] = 600 pg/mL, PBST buffer) | Signal within control limits: | (disposable) |
Common abbreviations: PBS = Phosphate-buffered saline, BSA = Bovine Serum Albumin, hIg = Human immunoglobulin protein, PSA = Prostate specific antigen, DMEM = Dulbecco’s Modified Eagle Medium, FBS = Fetal bovine serum, LPO = Lactoperoxidase.
Figure 3Schematic representation of an TNF-α aptasensor with methylene blue (MB) as a redox label. In the absence of the target, Apt hairpins remain folded with MB reporters in proximity to the electrode, ensuring efficient electron transfer and a measurable faradaic current. Upon target binding, the redox tag moves far away from the electrode and the redox current decreases. Reprinted from [106] with permission from The Royal Society of Chemistry.
Figure 4Schematic illustration of an electrochemical DNA biosensor for IFNγ based on hybridization chain reaction with enzyme-amplification. IFNγ partly quenches the recognition probes, while unbound recognition probes hybridize with the capture probes, followed by successive hybridization with biotinylated DNA hairpins. Tagged ALP dephosphorylates 1-NPP, which is further oxidized to 1-NP. Reprinted from [108] with permission from Elsevier.
Figure 5Preparation of ITO/PDOP-AuNP/Ab1 platform and HRP-Ab2-AuNP-PDOP@CNT Probe and sandwich type immunoassay. IL-6 binds to Ab1 and Ab2 and immobilizes HRP, which oxidizes 1,2-phenylenediamine in the presence of H2O2. Reprinted from [111] with permission from American Chemical Society.
Figure 6Schematic illustration of the different steps involved in the construction of an amperometric immunosensor for TGF-β1 using V-Phe-SWCNT hybrids. Ab1, HRP and a viologen were immobilized on SWCNT. Ab2 was immobilized via Bt-SAv on a screen printed carbon electrode (SPCE) grafted with carboxyl aryl diazonium. The signal generated by HRP catalyzed H2O2 reduction was amplified by the redox mediator viologen. Reprinted from [116] with permission from Elsevier.
Figure 7Schematic of (A) IFNγ ELISA assay followed in 96- or 384-well plates and (B) IFNγ amperometric assay followed in gold Au/PMMA/PCB plates. Oxidization of TMBred by HRP induces photometric change measured in ELISA, and a reduction current of TMBox is measured in the amperometric biosensor. Reprinted from [118] with permission from Elsevier.
Figure 8Schematic illustration of the steps involved in the preparation of the SPCE/MWCNT-IgG-Ab1-IL-1β-Ab2-Bt-SAv-ALP immunosensor by electro-click chemistry, where MWCNT is multi-walled carbon nanotubes. Ethynylated anti-Ab1 IgG is attached to azide-functionalized MWCNTs in the presence of Cu(I). Upon sandwich immunoreaction, ALP dephosphorylates 1-naphthyl phosphate to 1-naphthol, which is oxidized at the electrode. Reprinted from [123] with permission from Elsevier.
Figure 9Schematic illustration of the GCE/Fc-PNW/PDDA/AuNP/Ab1, GNR-GOx-Ab2 immunosensor for TNFα detec Table 1. Ab2 functionalized with gold nanorods (GNRs) and glucose oxidase (GOx) are brought close to the electrode upon sandwich immunoreaction. GOx converts glucose to gluconolactone. Reprinted from [124] with permission from Elsevier.
Figure 10Schematic illustration depicting the bio-functionalization steps of a ITO/P3/TNFα biosensor. (A) Process for generating P3 polymer. (B) Ab is immobilized on the ITO electrode via P3 linker, which captures TNFα. Reprinted from [96] with permission from Elsevier.
Figure 11Schematic illustrations of (A) the preparation of RGO-AuNPs nanocomposite, (B) assembly procedure of CNTs@QDs-anti-IL-6 Ab bionanolabel and (C) fabrication and measurement process of the competitive immunosensor. Surface bound IL-6 and sample IL-6 compete for binding with the bionanolabel, and the depletion in the bound Cd2+ is measured with stripping voltammetry on a heated SPCE, proportionate to the IL-6 concentration. Reprinted from [137] with permission from The Royal Society of Chemistry.
Figure 12Schematic illustrations of (A) the procedure for preparation of poly[G]- and avidin-functionalized SiNP conjugate and (B) the procedure and principle for electrochemical immunoassay. Sandwich immunoreaction of TNFα with Ab1 and Ab2 brings poly[G] close to the electrode, which undergoes oxidation, mediated by Ru(bpy)32+. Reprinted from [145] with permission from American Chemical Society.
Figure 13Schematic illustration of a magnetoimmunosensor for TNFα detection (a) Serum background is removed using magnetic beads coated with albumin and IgG antibodies. (b) The background removed sample is transferred to a new tube, and TNFα is then captured using magnetic bead coated with TNFα antibody. (c) The captured TNFα is eluted from the magnetic beads using 2% SDS at 63℃, and (d) the magnetic beads are separated out of the eluted sample. (e) Impedance spectra of the eluted sample are then analyzed using an EIS technique in which the CSGM electrode is employed as a platform for TNFα adsorption and for EIS analysis. R, W and C labeled on CSGM electrodes denote reference, working and counter electrodes, respectively. Nyquist plots represent impedance spectra recorded from (i) blank chip and (ii) eluted sample of 1pg/ml TNFα spiked in human serum. Reprinted from [99] with permission from Elsevier.
Figure 14Schematic illustration of the flow-injection immunoassay system for IL-6 determination. HRP-labeled anti-IL-6 Ab immobilized on a SPCE coated with AuNPs generate redox signal with thionine and H2O2 substrates. This coupled reaction is hindered with IL-6 binding. Reprinted from [101] with permission from Elsevier.
Figure 15(A) Schematic illustration depicting the reaction of 1-pyrenebutanoic acid succinimidyl ester (PASE) with IL-6 Apt forming the IL-6 aptamer PASE complex. Schematic illustrations of the CNT FET sensor functionalized with (B) IL-6 Apt PASE complex as positive control, (C) IgG as a negative control and (D) tween-20 blocking agent as a negative control. Reprinted from [100] with permission from MDPI.
Figure 16Schematic illustration of a PS-Cd2+-anti-IL-6 Ab, PS-Fc-anti-IL-17 Ab immunosensor for multiplexed detection of IL-6 and IL-17. Upon sandwich immunoreaction, two current peaks are generated with SWV, corresponding to the reduction in Cd2+ and Fc. Reprinted from [153] with permission from Elsevier.
Figure 17(a) Schematic illustration of a magnetoimmunosensor for the simultaneous determination of IL-8 mRNA and IL-8. (b) Photograph of the SPdCE and the magnet holding block (top), and the modified Mbs on the SPdCE assembled on the magnet holding block dipped in a solution (bottom). Reprinted from [156] with permission from Elsevier.